HDGFL3: A promising drug target and biomarker for hepatoma (G50810)

Target Name: HDGFL3

NCBI ID: G50810

HDGFL3

HDGFL3: A promising drug target and biomarker for hepatoma

Hepatoma-derived growth factor 2 (HDGFL3) is a protein that has been identified as a potential drug target and biomarker for hepatoma, a type of liver cancer. The liver is a vital organ that is responsible for filtering the blood, detoxifying harmful substances, and producing bile to aid in digestion. However, due to its location in the body and the speed at which it grows, the liver is also prone to cancer.

HDGFL3 is a transmembrane protein that is expressed in various tissues and organs, including the liver, pancreas, and blood vessels. It is involved in the regulation of cell growth, differentiation, and survival. The primary function of HDGFL3 is to induce the production of the PDGF receptor, which is a critical signaling pathway in cancer development.

In addition to its role in cancer development, HDGFL3 has also been shown to play a key role in the regulation of normal tissue growth and development. It is involved in the development and maintenance of tissues such as the liver, pancreas, and blood vessels, and has been shown to promote the growth and proliferation of these tissues.

This protein has also been shown to play a key role in the regulation of the immune response. It has been shown to interact with immune cells and to regulate the production of immune responses. This suggests that HDGFL3 may have potential as a therapeutic agent for immune -related diseases.

Due to its involvement in the regulation of cell growth, differentiation, and survival, HDGFL3 has been identified as a potential drug target for hepatoma. Studies have shown that HDGFL3 can promote the growth and proliferation of liver cancer cells in a culture dish, and that it can also enhance the resistance of these cells to chemotherapy. This suggests that HDGFL3 may be an effective target for the treatment of hepatoma.

In addition to its potential as a drug target, HDGFL3 has also been shown to be a potential biomarker for hepatoma. Studies have shown that HDGFL3 levels are elevated in the blood and liver of patients with hepatoma, and that they can be used as a diagnostic marker for this disease. This suggests that HDGFL3 may be a valuable diagnostic tool for the diagnosis and treatment of hepatoma.

In conclusion, HDGFL3 is a protein that has been shown to play a key role in the regulation of cell growth, differentiation, and survival. Its potential as a drug target and biomarker for hepatoma makes it an attractive target for further research. Further studies are needed to fully understand the role of HDGFL3 in cancer development and to determine its potential as a therapeutic agent.

Protein Name: HDGF Like 3

Functions: Enhances DNA synthesis and may play a role in cell proliferation

The "HDGFL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HDGFL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets